Clinical Trials Logo

Filter by:
NCT ID: NCT05589506 Enrolling by invitation - Prosthesis Survival Clinical Trials

Partial Rehabilitation Using a PEEK-acrylic Resin Removable Partial Denture

PEEKPilotRPD
Start date: December 13, 2019
Phase: N/A
Study type: Interventional

The goal of this observational study is to evaluate the outcome of a Poly-ether-ether-ketone - acrylic resin removable partial denture used in partial edentulous rehabilitation after one year of follow-up. The main question it aims to answer is: - What is the survival outcome of partial rehabilitations using Poly-ether-ether-ketone-acrylic resin removable partial dentures? The participants will receive a definitive removable partial denture incorporating Poly-ether-ehter-ketone.

NCT ID: NCT05583045 Enrolling by invitation - Clinical trials for Diabetes Mellitus, Type 2

Prediabetes Intervention With Tea

PREVENT
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The goal of this interventional study is investigating the effect of the daily consumption of olive leaves tea on glycemic control of individuals diagnosed with pre-diabetes. The hypothesis of this study is that the integration of olive leaf tea on daily food consumption will favors glycemic control and ameliorate insulin resistance in individuals with pre-diabetes.

NCT ID: NCT05320354 Enrolling by invitation - Clinical trials for Periprosthetic Joint Infection

Diagnosis and Bacterial Identification of Periprosthetic Joint Infection With Microbial-ID

MID
Start date: April 25, 2022
Phase:
Study type: Observational

The primary objective of this study is to demonstrate the validity of the Microbial- ID test to aid in diagnosis of periprosthetic joint infection (PJI) in terms of sensitivity and specificity.

NCT ID: NCT05054075 Enrolling by invitation - COVID-19 Clinical Trials

Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and COVID-19 lineage infection. The Methodology concerns in silico procedures using organic fluids from 54 bivalves (in very specific conditions) to evaluate their therapeutic effects in 6 voluntary SARS and COVID-19 infected persons with an integrative diagnosis by a computational Mora®Nova apparatus to access the basal and experimental human physiological parameters.

NCT ID: NCT04932902 Enrolling by invitation - Priapism Clinical Trials

ManAgement of pRiapiSm and Its Impact on Outcomes

MARS
Start date: June 1, 2021
Phase:
Study type: Observational

Priapism is a urological emergency that is defined as a prolonged penile erection lasting more than 4 h, remaining despite orgasm and in the absence of sexual stimulation. There are three sub-types of priapism: Ischaemic, non- ischaemic and stuttering. The most common (95% cases) of these is ischaemic priapism (IP), which represents a compartment syndrome of the corpus cavernosa with minimal or no arterial flow into the penis. It causes time-dependent smooth muscle damage that can result in significant morbidity (including, permanent erectile dysfunction (ED), penile shortening, penile curvature and loss of girth) with- out prompt intervention. Unlike ischemic priapism, non-ischemic priapism is not a urologic emergency, both the American Urological Association (AUA) and the European Association of Urology (EAU) recommend conservative, non-operative, management for the treatment of NIP. Spontaneous resolution has been documented to occur in 62% of patients [1]. Despite the very high burden of priapism and its time-dependent adverse effect on erectile function, few studies have comprehensively defined the clinical epidemiology of this complication nor have any compared sexual dysfunction in men with SCD with that in those without it. Evidence-based treatment strategies for priapism are currently lacking, especially in terms of sexual function. However, despite the various publications in the literature, even today the published studies show considerable bias, in terms of sample size, evaluation of reproducible outcomes, use of internationally validated questionnaires, well-defined follow-up evaluation, as well as the evaluation of outcome after medical or surgical treatment. For this reason, the purpose of this international register is precisely to shed light on what may be the responses to medical surgical treatment in patients with priapism, but in particular to set up a rational data collection that has solid scientific bases.

NCT ID: NCT04848506 Enrolling by invitation - Clinical trials for Symptomatic Hypertrophic Cardiomyopathy (HCM)

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

FOREST-HCM
Start date: May 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to collect long-term safety and tolerability data for aficamten (CK-3773274)

NCT ID: NCT04762992 Enrolling by invitation - Pre-Eclampsia Clinical Trials

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

HepaGrowth
Start date: July 6, 2023
Phase: Phase 3
Study type: Interventional

Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality (Miller et al. 2008, Nardozza et al. 2017). Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.

NCT ID: NCT04574076 Enrolling by invitation - Haemophilia A Clinical Trials

A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®

pathfinder9
Start date: October 23, 2020
Phase:
Study type: Observational

This study will collect information on side effects and how well Esperoct® (turoctocog alfa pegol (N8-GP)) works during long-term treatment (prophylaxis) in males with haemophilia A. Participants in this study will get the same treatment as they would normally get, if they were not participating in the study. All visits at the clinic are done in the same way as participants are used to, when visiting their doctor. During visits at the clinic participants might be asked for some relevant tests if considered useful by the study doctor. During the visits the study doctor might ask if participants had any side effects since the last study visit. Participants will be asked to note down in their own diary the number of bleeds and how these were treated, as well as their regular prophylaxis. Participation in the study will last for about 5-7 years, depending on when participants join the study. Participants are free to leave the study at any time and for any reason. This will not affect their current and future medical care.

NCT ID: NCT04451044 Enrolling by invitation - Clinical trials for Coronary Artery Disease

Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

DEFINE GPS
Start date: June 17, 2021
Phase: N/A
Study type: Interventional

Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.

NCT ID: NCT04421963 Enrolling by invitation - Breast Cancer Clinical Trials

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

ROSY-O
Start date: August 4, 2020
Phase: Phase 3
Study type: Interventional

The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.